

Introduction to Survival Analysis

Jianan Hui

2/19/2015

Outline

1. Introduction
2. Kaplan-Meier Survival Curves
3. The Log-Rank Test
4. Cox Proportional Hazards Model

Introduction



- **Survival analysis:**
 - method for analyzing timing of events;
 - data analytic approach to estimate the time until an event occurs.
- Historically, **survival time** refers to the time that an individual “survives” over some period until the **event** of death occurs.
- **Event** is also named **failure**.

Areas of application



- Survival analysis is used as a tool in many different settings:
 - proving or disproving the value of medical treatments for diseases;
 - evaluating reliability of technical equipment;
 - monitoring social phenomena like divorce and unemployment.

Examples




- › Time from...
 - › **marriage to divorce;**
 - › **birth to cancer diagnosis;**
 - › **entry to a study to relapse.**

Censoring




- ▶ The survival time is not known exactly! This may occur due to the following reasons:
 - ▶ a person does not experience the event before the study ends;
 - ▶ a person is lost to follow-up during the study period;
 - ▶ a person withdraws from the study because of some other reason.

Right Censored



X = Event occurs

Left censored



Outcome variable



- › Time until an event occurs
- › $T =$ survival time ($T > 0$)
- › T is a random variable
- › $t =$ specific value of interest for T
- › Ask whether $T > t$ if we are interested in the question whether an individual survives longer than t .

Survivor function





- ▶ $S(t) = P(T > t)$
- ▶ Probability that random variable T exceeds specified time t
- ▶ Fundamental to survival analysis

t	$S(t)$
1	$S(1) = P(T > 1)$
2	$S(2) = P(T > 2)$
3	$S(3) = P(T > 3)$
.	.
.	.
.	.

Survivor function

$$S(t) = \Pr(T > t)$$



Hazard function



$$h(t) = \lim_{\Delta t \rightarrow 0} \frac{P(t \leq T \leq t + \Delta t \mid T \geq t)}{\Delta t}$$

- Often called: Conditional failure rate
- $h(t)$ has no upper bounds
- Depends on whether time is measured in days, weeks, months, or years, etc. (Example next page)

Example: Hazard function



Assume having a huge follow-up study on heart attacks:

- 600 heart attacks (events) per year;
- 50 events per month;
- 11.5 events per week;
- 0.0011 events per minute.

$h(t)$ = rate of events occurring per time unit

Relation between $S(t)$ and $h(t)$




- › If T continuous:

$$S(t) = \exp\left[-\int_0^t h(u) du\right]$$

$$h(t) = -\frac{S'(t)}{S(t)}$$

Example: Relationship



Types of hazard functions




Exponential

with constant rate $\lambda = 0.5$




Increasing Weibull

with shape = 5 & scale = 10




Decreasing Weibull

with shape = 0.2 & scale = 10



Lognormal

with $\sigma = 0.5$



Goals (of survival analysis)



- › to **estimate** and **interpret** survivor and/or hazard function;
- › to **compare** survivors and/or hazard functions;
- › to assess the **relationship of explanatory variables** to survival times -> we need mathematical modelling (**Cox model**).


Computer layout



individual	t (in weeks)	δ (failed or censored)
1	5	1
2	12	0
3	3.5	0
4	8	0
5	6	0
6	3.5	1

Notation & terminology



- Ordered failures: **unordered** 
 - ~~censored t's~~
 - failed t's
 - ordered ($t_{(i)}$)
- Frequency counts:
 - $m_i = \#$ individuals who failed at $t_{(i)}$
 - $q_i = \#$ ind. censored in $[t_{(i)}, t_{(i+1)})$
- Risk set $R(t_{(i)})$: Collection of individuals who have survived at least until time $t_{(i)}$

Manual analysis layout



Ordered failure times	# of failures m_i	# censored in $[t_{(i)}, t_{(i+1)})$	Risk set $R(t_{(i)})$
$t_{(0)}=0$	m_i	q_0	$R(t_{(0)})$
$t_{(1)}$	m_1	q_1	$R(t_{(1)})$
....
$t_{(k)}$	m_k	q_k	$R(t_{(k)})$

Manual analysis layout



Ordered failure times	# of failures m_i	# censored in $[t_{(i)}, t_{(i+1)})$	Risk set $R(t_{(i)})$
$t_{(0)} = 0$	0	0	6 persons survive ≥ 0 weeks
$t_{(1)} = 3.5$	1	1	6 persons survive ≥ 3.5 weeks
$t_{(2)} = 5$	1	3	4 persons survive ≥ 5 weeks

2 Kaplan-Meier Curves

■ Example

The data: remission times (weeks) for two groups of leukemia patients

Group 1 (n=21) treatment	Group 2 (n=21) placebo	# failed	# censored	Total
6, 6, 6, 7, 10, 13, 16, 22, 23, 6+, 9+, 10+, 11+, 17+, 19+, 20+, 25+, 32+, 32+, 34+, 25+	1, 1, 2, 2, 3, 4, 4, 5, 5, 8, 8, 8, 8, 11, 11, 12, 12, 15, 17, 22, 23	9	12	21
		21	0	21

Descriptive statistic:

$$\bar{T}_1(\text{ignoring } +'s) = 17.1, \quad \bar{T}_2 = 8.6$$

+ denotes censored

■ Table of ordered failure times

Group 1 (treatment)

$t_{(j)}$	n_j	m_j	q_j
0	21	0	0
6	21	3	1
7	17	1	1
10	15	1	2
13	12	1	0
16	11	1	3
22	7	1	0
23	6	1	5
>23	-	-	-

Group 2 (placebo)

$t_{(j)}$	n_j	m_j	q_j
0	21	0	0
1	21	2	0
2	19	2	0
3	17	1	0
4	16	2	0
5	14	2	0
8	12	4	0
11	8	2	0
12	6	2	0
15	4	1	0
17	3	1	0
22	2	1	0
23	1	1	0

Group 1 (treatment)	Group 2 (placebo)
6, 6, 6, 7, 10, 13, 16, 22, 23, 6+, 9+, 10+, 11+, 17+, 19+, 20+, 25+, 32+, 32+, 34+, 25+	1, 1, 2, 2, 3, 4, 4, 5, 5, 8, 8, 8, 8, 11, 11, 12, 12, 15, 17, 22, 23

+ denotes censored

→ Remark: no censorship in group 2

■ **Computation of KM-curve for group 2 (no censoring)**

$t_{(j)}$	n_j	m_j	q_j	$\hat{S}(t_{(j)})$
0	21	0	0	1
1	21	2	0	19/21 = .90
2	19	2	0	17/21 = .81
3	17	1	0	16/21 = .76
4	16	2	0	14/21 = .67
5	14	2	0	12/21 = .57
8	12	4	0	8/21 = .38
11	8	2	0	6/21 = .29
12	6	2	0	4/21 = .19
15	4	1	0	3/21 = .14
17	3	1	0	2/21 = .10
22	2	1	0	1/21 = .05
23	1	1	0	0/21 = .00

$$\hat{S}(t_{(j)}) = \frac{\# \text{ surviving past } t_{(j)}}{21}$$

KM Curve for Group 2 (Placebo)


```

> time2 <-
c(1,1,2,2,3,4,4,5,5,8,8,8,8,11,11,12,12,15,17,
22,23)
> status2 <-
c(1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1)

> fit2 <- survfit(Surv(time2, status2) ~ 1)

> plot(fit2,conf.int=0, col = 'red', xlab =
'Time (weeks)', ylab = 'Survival Probability')
> title(main='KM Curve for Group 2 (placebo)')

```



General KM formula

- Alternative way to calculate the survival probabilities
- KM formula = product limit formula

$$\begin{aligned}\hat{S}(t_{(j)}) &= \prod_{i=1}^j \hat{Pr}(T > t_{(i)} \mid T \geq t_{(i)}) \\ &= \hat{S}(t_{(j-1)}) \times \hat{Pr}(T > t_{(j)} \mid T \geq t_{(j)})\end{aligned}$$

Computation of KM-curve for group 1 (treatment)

$t_{(j)}$	n_j	m_j	q_j	$\hat{S}(t_{(j)})$
0	21	0	0	1
6	21	3	1	$1 \times 18/21 = .8571$
7	17	1	1	$.8571 \times 16/17 = .8067$
10	15	1	2	
13	12	1	0	
16	11	1	3	
22	7	1	0	
23	6	1	5	

Fraction at $t_{(j)}$:
 $\Pr(T > t_{(j)} \mid T \geq t_{(j)})$

$= \frac{n_j - m_j}{n_j}$

Computation of KM-curve for group 1 (treatment)

$t_{(j)}$	n_j	m_j	q_j	$\hat{S}(t_{(j)})$
0	21	0	0	1
6	21	3	1	$1 \times \frac{18}{21} = .8571$
7	17	1	1	$.8571 \times \frac{16}{17} = .8067$
10	15	1	2	$.8067 \times \frac{14}{15} = .7529$
13	12	1	0	$.7529 \times \frac{11}{12} = .6902$
16	11	1	3	$.6902 \times \frac{10}{11} = .6275$
22	7	1	0	$.6275 \times \frac{6}{7} = .5378$
23	6	1	5	$.5378 \times \frac{5}{6} = .4482$


Fraction at $t_{(j)}$:
 $\Pr(T > t_{(j)} \mid T \geq t_{(j)})$

KM-curve for group 1 (treatment)

```

> time1 <-
c(6,6,6,7,10,13,16,22,23,6,9,10,11,17,19,20,
25,32,32,34,35)
> status1 <-
c(1,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0)
> fit1 <- survfit(Surv(time1, status1) ~ 1)
> plot(fit1,conf.int=0, col = 'red', xlab =
'Time (weeks)', ylab = 'Survival
Probability')
> title(main='KM Curve for Group 1
(treatment)')

```




Comparison of KM Plots for Remission Data



KM-Curves for Remission Data

```
> time1 <-  
c(6,6,6,7,10,13,16,22,23,6,9,10,11,17,19,20,25  
,32,32,34,35)  
> status1 <-  
c(1,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0)  
  
> time2 <-  
c(1,1,2,2,3,4,4,5,5,8,8,8,8,11,11,12,12,15,17,  
22,23)  
> status2 <-  
c(1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1)  
  
> fit1 <- survfit(Surv(time1, status1) ~ 1)  
> fit2 <- survfit(Surv(time2, status2) ~ 1)  
  
> plot(fit1,conf.int=0, col = 'blue', xlab =  
'Time (weeks)', ylab = 'Survival Probability')  
> lines(fit2, col = 'red')  
> legend(21,1,c('Group 1 (treatment)', 'Group  
2 (placebo)'), col = c('blue','red'), lty = 1)  
> title(main='KM-Curves for Remission Data')
```



→ Question: Do we have any reason to claim that group 1 (treatment) has better survival prognosis than group 2?